A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Achillion survived a 50M dilutive financing in August to rise significantly after the initiation of the phase II trial of ACH-1625. These events mean that Achillion will end the year with a comfortable cash cushion but also a bloated market cap which is now disproportionate to their risk/benefit ratio. I doubt 28 day data on ACH-1625 will be remarkable enough to lift the share price in early 2011, leaving the rest of 2011 before 12 week data provides a more substantial catalyst. In the meantime, the stock will remain exquisitely vulnerable to broad market pullbacks. In addition, the most recent PR fails to mention elvucitabine, which makes me wonder if this compound is simply pipeline window dressing.